Pharvaris
Giorgio Giannattasio is currently the Vice President, Head of Medical Affairs for Immunology and Rare Diseases, specifically Hereditary Angioedema, at Pharvaris. Prior to this role, Giannattasio held positions at Alexion Pharmaceuticals, Takeda, and Biogen, where Giorgio specialized in global medical affairs for various rare diseases and neurological conditions. Giorgio has a strong academic background with a PhD in Clinical Pathophysiology and Experimental Medicine from the University of Naples Federico II, where Giorgio also completed their MD residency in Clinical Immunology and Allergy. Additionally, Giorgio has experience as a Post-Doctoral Research Fellow at Harvard Medical School and Brigham and Women's Hospital.
This person is not in any teams
Pharvaris
2 followers
Pharvaris is a preclinical stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients for use as an alternative to injected therapies for hereditary angioedema (HAE) and other B2 receptor-mediated indications. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.